Skip to main content

GoodRx Holdings Inc

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

GDRX$3.54-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules

(a)(1) Financial Statements

Our consolidated financial statements are included in this Annual Report on Form 10-K beginning on page F-1.

(a)(2) Financial Statement Schedules

All financial statement schedules have been omitted because they are not applicable, not material or because the information required is already included in the consolidated financial statements or the notes thereto.

(a)(3) Exhibits

The exhibits listed below are filed as part of this Annual Report on Form 10-K or are incorporated herein by reference, in each case as indicated below.

ExhibitNumber · Exhibit Description · Incorporated by Reference · Filed/FurnishedHerewith
Form · File No. · Exhibit · FilingDate
3.1Amended and Restated Certificate of Incorporation8-K001-395493.19/28/20
3.2Amended and Restated Bylaws8-K001-395493.29/28/20
4.1Form of Certificate of Class A Common StockS-1333-2484654.18/28/20
4.2Form of Certificate of Class B Common StockS-8333-2490694.49/25/20
4.3Description of Capital Stock*
4.4Amended and Restated Stockholders Agreement by and between GoodRx Holdings, Inc. and certain security holders of GoodRx Holdings, Inc., dated October 12, 2018S-1333-2484654.28/28/20
4.5Stockholders Agreement by and between GoodRx Holdings, Inc. and certain security holders of GoodRx Holdings, Inc., dated September 22, 20208-K001-3954910.19/28/20
4.6Amended and Restated Investor Rights Agreement by and between GoodRx Holdings, Inc. and certain security holders of GoodRx Holdings, Inc., dated October 12, 2018S-1333-2484654.48/28/20
10.1†Form of Indemnification Agreement between GoodRx Holdings, Inc. and its directors and officersS-1/A333-24846510.19/14/20
10.2†Fifth Amended and Restated 2015 Equity Incentive Plan10-Q001-3954910.211/12/20
10.3†2020 Incentive Award PlanS-1/A333-24846510.39/14/20
10.3.1†Form of Option Agreement pursuant to 2020 Incentive Award PlanS-1/A333-24846510.3.19/14/20
10.3.2†Form of Restricted Stock Unit Agreement pursuant to 2020 Incentive Award PlanS-1/A333-24846510.3.29/14/20
10.3.3†Form of Time-Vesting Restricted Stock Unit Award Agreement (Founders) pursuant to 2020 Incentive Award PlanS-1/A333-24846510.3.39/14/20
10.3.4†Form of Performance-Vesting Restricted Stock Unit Award Agreement (Founders) pursuant to 2020 Incentive Award PlanS-1/A333-24846510.3.49/14/20
10.3.5†First Amendment to 2020 Incentive Award Plan10-Q001-3954910.15/13/21
10.4†GoodRx Holdings, Inc. 2020 Employee Stock Purchase PlanS-1/A333-24846510.49/14/20
10.5†GoodRx Holdings, Inc. Director Compensation ProgramS-1/A333-24846510.59/14/20
10.6†Second Amended and Restated Employment Agreement, by and between GoodRx, Inc. and Trevor Bezdek, dated April 25, 20238-K001-3954910.24/25/23
10.7†Second Amended and Restated Employment Agreement, by and between GoodRx, Inc. and Douglas Hirsch, dated April 25, 20238-K001-3954910.34/25/23
10.8†Offer Letter for Bansi Nagji, dated March 28, 202010-K001-3954910.103/11/21
10.9†Offer Letter for Karsten Voermann, effective February 12, 202010-K001-3954910.113/11/21
10.10.1+First Lien Credit Agreement by and among GoodRx, Inc., GoodRx Intermediate Holdings, LLC, the lenders party thereto, Barclays Bank PLC and the joint lead arrangers and joint lead bookrunners party thereto, dated October 12, 2018S-1/A333-24846510.138/28/20
10.10.2+First Lien Security Agreement by and among GoodRx, Inc., GoodRx Intermediate Holdings, LLC., Iodine, Inc., and Barclays Bank PLC, dated October 12, 2018S-1/A333-24846510.168/28/20
10.10.3+First Lien Guaranty by and among GoodRx, Inc., GoodRx Intermediate Holdings, LLC, Iodine, Inc. and Barclays Bank PLC, dated October 12, 2018S-1/A333-24846510.178/28/20
10.10.4+First Incremental Amendment to First Lien Credit Agreement by and between GoodRx, Inc., GoodRx Intermediate Holdings, LLC, Iodine, Inc., HeyDoctor, LLC, the lenders party thereto and Barclays Bank PLC, dated November 1, 2019S-1/A333-24846510.148/28/20
10.10.5+Second Incremental Amendment to First Lien Credit Agreement by and between GoodRx, Inc., GoodRx Intermediate Holdings, LLC, Iodine, Inc., HeyDoctor, LLC, Lighthouse Acquisition Corp., the lenders party thereto and Barclays Bank PLC, dated May 12, 2020S-1/A333-24846510.158/28/20
10.10.6+Third Amendment to First Lien Credit Agreement, dated June 29, 202310-Q001-3954910.58/9/23
10.10.7+Fourth Amendment to First Lien Credit Agreement, dated July 7, 202310-Q001-3954910.68/9/23
10.11.1^+Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated September 6, 2019S-1/A333-24846510.198/28/20
10.11.2^First Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated August 14, 202010-Q001-3954910.18/12/21
10.11.3^+Second Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated May 27, 202110-Q001-3954910.28/12/21
10.11.4Third Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated March 18, 202210-Q001-3954910.15/10/22
10.12^+Stock Purchase Agreement, dated as of March 6, 2022, by and between GoodRx, Inc. and TherapeuticsMD, Inc.10-Q001-3954910.25/10/22
10.13†Offer Letter for Romin Nabiey, effective May 1, 201710-K001-3954910.193/1/23
10.14†Offer Letter for Raj Beri, dated May 6, 20228-K001-3954910.15/9/22
10.15†+Employment Agreement, by and between GoodRx, Inc. and Scott Wagner, dated April 25, 20238-K001-3954910.14/25/23
10.16†Letter Agreement, by and between GoodRx, Inc. and Raj Beri, dated May 30, 20238-K001-3954910.16/2/23
10.17†+Separation Agreement & Release, by and among GoodRx Holdings, Inc., GoodRx, Inc. and Babak Azad, dated July 19, 20238-K001-3954910.17/27/23
10.18†Non-Employee Director Deferred Compensation Plan*
10.18.1†Form of Director Deferred Cash Fees RSU Agreement*
10.18.2†Form of Director Deferred RSU Agreement*
21.1List of Subsidiaries of GoodRx Holdings, Inc.*
23.1Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm*
31.1Rule 13a-14(a)/15d-14(a) Certification of Interim Chief Executive Officer*
31.2Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer*
32.1Section 1350 Certification of Interim Chief Executive Officer**
32.2Section 1350 Certification of Chief Financial Officer**
97.1†GoodRx Holdings Inc. Policy for Recovery of Erroneously Awarded Compensation*
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document*
101.SCHInline XBRL Taxonomy Extension Schema Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
  • Filed herewith.

** Furnished herewith.

† Indicates management contract or compensatory plan.

^ Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is treated as confidential by the Company.

  • The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5)(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.